Strides Arcolab Receives FDA Approval for Two Generic Cancer Drugs

by Kathy Jones on  November 25, 2011 at 8:10 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Bangalore based pharmaceutical company Strides Arcolab has revealed that its subsidiary company, Onco Therapies Ltd has received approval from the US Food and Drug Administration to market two generic cancer drugs in the American market.
 Strides Arcolab Receives FDA Approval for Two Generic Cancer Drugs
Strides Arcolab Receives FDA Approval for Two Generic Cancer Drugs

The company said that it has been given permission to market Injectable Carboplatin in strengths of 10 mg/mL and packaged in 1,000 mg/100 mL pharmacy bulk packages and Oxaliplatin USP in 50-mg and 100-mg single-use vials in the United States.

Stating that it will be launching carboplatin in the near future, the company said, "Carboplatin is part of the oncology portfolio licensed to Pfizer in January, 2010, for the US market and is expected to be launched shortly".

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Cancer and Homeopathy Cancer Facts Cancer Tattoos A Body Art Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...